Video

Novel HIV vaccine induces durable immune responses

View on the News

HIV vaccine looks very promising

The 1-year results for this new HIV vaccine and now the 1-year follow-up results appear very promising for its future prospects in wider clinical testing.

What’s especially interesting about the data reported for this vaccine so far is that the developers also tested the vaccine in rhesus monkeys and showed similar immunologic induction and a 67% efficacy for protecting against repeated challenges with a simian-human immunodeficiency virus. This level of protection against infection and the similar cellular and antibody responses to the vaccine and booster in the animal model and in people is encouraging. The vaccine protected monkeys. Now we need to find out whether it will protect humans.

Dr. R. Brad Jones, Cornell University, New York Mitchel L. Zoler/MDedge News

Dr. R. Brad Jones

R. Brad Jones, PhD , is an immunologist at Cornell University, New York. He had no disclosures. He made these comments during a talk at the conference.


 

REPORTING FROM AIDS 2018

An investigational HIV vaccine that recently began testing in a phase IIb trial showed durable safety and anti-HIV immune responses out to 1 year following the final dosage in the initial phase I/IIa trial that had identified the most effective dosing strategy for the vaccine.

The 96-week follow-up data showed durable humoral and cellular immunity induction by the vaccine and its associated booster, a durable breadth of immune responses to the multiple HIV clades that the vaccine targets, and no serious or grade 3 or 4 adverse effects in the 393 people who participated in the early-phase study, Frank L. Tomaka, MD, said at the 22nd International AIDS Conference.

The 96-week results he reported came from follow-up of the 393 people who received one of several different dosing regimens for an engineered, mosaic HIV vaccine. The vaccine incorporates genes for three different HIV envelope antigens that contain components drawn from several different HIV clades (to induce more broadly protective immunity) into a serotype 26 adenovirus. The immunization regimen also includes treatment with HIV glycoprotein 140 as a booster agent. Dr. Tomaka and his associates reported the primary endpoints from this placebo-controlled study, APPROACH, measured just after the fourth and final immunizing regimen at 48 weeks after the first treatment in a recently published article (Lancet. 2018 Jul 21;392[10143]:232-43).


As part of the study, the investigators administered the vaccine and booster to rhesus monkeys and found that the regimens produced a pattern of immune responses in the monkeys similar to that seen in people. When the monkeys that received the regimen that performed best in people received six monthly challenges with a simian-human immunodeficiency virus that’s related to HIV, the researchers found a 67% efficacy for protection against infection. These “very encouraging” findings led the company developing the vaccine to launch in November 2017 a phase IIb trial, named Imbokodo, in five African countries, with a plan to enroll 2,600 people, Dr. Tomaka said.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

“What’s unique and very exciting” about the APPROACH findings are the nonhuman primate findings, and the fact that the vaccine was designed to provide protection against several different HIV clades, Dr. Tomaka said in a video interview. The 67% level of protection against viral challenge in the monkeys is at a level that would be clinically meaningful if replicated in people. A vaccine and booster regimen that provided something in the range of 50%-60% protection or better might be an attractive option in a region with relatively low resources, while in a more developed country a vaccine with a protective efficacy of 70% or better would also likely be seen as an attractive intervention, said Dr. Tomaka, clinical leader for HIV/STI vaccines for Janssen in Titusville, N.J.

SOURCE: Tomaka FL et al. AIDS 2018, Abstract TUAA0104.

Next Article: